Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Hira Rizvi"'
Autor:
Diana Saravia, Andrew J. Plodkowski, Annapaola Mariniello, Benjamin Besse, Lizza E.L. Hendriks, Maria Lucia Reale, Fabrizio Tabbò, Gilberto Lopes, Lydie Cassard, Anne-Marie C. Dingemans, Kathryn C. Arbour, Matthew D. Hellmann, Margarita Majem, Hira Rizvi, Edouard Auclin, Jeffrey Girshman, Silvia Novello, M. Naigeon, Simona Carnio, Nathalie Cozic, F. Blanc-Durand, Laura Mezquita, Clarisse Audigier-Valette, Peter Sawan, Paolo Bironzo, Nathalie Chaput, Jose Carlos Ruffinelli, Luis Paz-Ares, Patricia Martin-Romano, Ernest Nadal, Melinda Charrier, Wungki Park, Isabel Ruth Preeshagul, David Planchard, Santiago Ponce, Gérard Zalcman, Caroline Rossoni
Publikováno v:
EUROPEAN JOURNAL OF CANCER
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
Instituto de Salud Carlos III (ISCIII)
European Journal of Cancer, 151, 211-220. ELSEVIER SCI LTD
European Journal of Cancer, 151, 211-220. Elsevier Ltd.
Background: dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils], correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non-small-cell lung cancer (aNSCLC). However, dNLR is dynamic under therapy and its longitud
Autor:
Alexander Drilon, David Hoyos, M. Offin, Jia Luo, Paul K. Paik, A. Iqbal, Chaitanya Bandlamudi, Kathryn C. Arbour, Matthew D. Hellmann, Marjorie G. Zauderer, Benjamin D. Greenbaum, Marta Łuksza, Mark T.A. Donoghue, Kenneth K.-S. Ng, Bob T. Li, R.M. Daly, Adam J. Schoenfeld, Hira Rizvi, Helena A. Yu, Isabel Ruth Preeshagul, Caroline G. McCarthy, Jamie E. Chaft, Charles M. Rudin, Gregory J Riely, Juliana Eng, Jacklynn V. Egger, Azadeh Namakydoust, W.V. Lai, Mark G. Kris, Christina Falcon, Piro Lito
Publikováno v:
Annals of Oncology
Structured Abstract Background Patients with lung cancers may have disproportionately severe COVID-19 outcomes. Understanding the patient-specific and cancer-specific features that impact severity of COVID-19 may inform optimal cancer care during thi
Autor:
Natasha Rekhtman, Marc Ladanyi, Hiroki Sato, Daisuke Kubota, Maria E. Arcila, Jason C. Chang, Dana Pe'er, Paul K. Paik, Adam J. Schoenfeld, Hira Rizvi, Helena A. Yu, Monika A. Davare, Romel Somwar, Michael Offin, Yahya Daneshbod, Ujwal Shinde, Mark G. Kris, Joseph M. Chan, Gregory J. Riely
Publikováno v:
Clinical Cancer Research. 26:2654-2663
Purpose: Patterns of resistance to first-line osimertinib are not well-established and have primarily been evaluated using plasma assays, which cannot detect histologic transformation and have differential sensitivity for copy number changes and chro
Autor:
Jennifer L. Sauter, Barry S. Taylor, Andrew J. Plodkowski, Mark T.A. Donoghue, Charles M. Rudin, Adam J. Schoenfeld, Peter Sawan, William D. Travis, Gregory J. Riely, Jacklynn V. Egger, Marc Ladanyi, Kathryn C. Arbour, Matthew D. Hellmann, Amanda Beras, Rocio Perez-Johnston, Natasha Rekhtman, Hira Rizvi, Chaitanya Bandlamudi
Publikováno v:
Ann Oncol
BACKGROUND: PD-L1 expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tu
Autor:
Andrew J. Plodkowski, Dung T. Le, Juan C. Osorio, Jennifer N. Durham, Hira Rizvi, Helena A. Yu, Michelle S. Ginsberg, Gregory J. Riely, Jamie E. Chaft, Luis A. Diaz, Peter Sawan, Joseph G. Crompton, Azadeh Namakydoust, Kathryn C. Arbour, Matthew D. Hellmann, Darragh Halpenny, Barzin Y. Nabet
Publikováno v:
J Clin Oncol
PURPOSE Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity from the periphery may also be an important contribu
Autor:
Mark G. Kris, Shirish M. Gadgeel, Hira Rizvi, Helena A. Yu, Adam J. Schoenfeld, G. J. Riely, Jeffrey Girshman, A. Iqbal, Kathryn C. Arbour, Matthew D. Hellmann
Publikováno v:
Annals of Oncology
Background Concurrent programmed death-ligand-1 (PD-(L)1) plus osimertinib is associated with severe immune related adverse events (irAE) in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). Now that PD-(L)1 inhibitor
Autor:
Maria E. Arcila, Charles M. Rudin, Glenn Heller, Adam J. Schoenfeld, Gregory J. Riely, Marc Ladanyi, Jessica Flynn, Hira Rizvi, Mark G. Kris, Helena A. Yu, Noura J. Choudhury, Christina Falcon
Publikováno v:
Clin Cancer Res
Purpose: EGFR exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell lung cancer (NSCLC) for which targeted therapies are under development. We sought to describe treatment outcomes and genomic and immunophenotypic characteristics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ab74d61f0f759a9ab027ae10ff52f8
https://europepmc.org/articles/PMC8127357/
https://europepmc.org/articles/PMC8127357/
Autor:
Nikolaus Schultz, Edward B. Garon, Maria E. Arcila, Michelle DeVeaux, Scott N. Gettinger, Zongzhi Liu, Katerina Politi, Christine A. Lydon, Anna Wurtz, Andrew J. Plodkowski, Gregory J. Riely, A. Truini, Hira Rizvi, J. Killam, Helena A. Yu, Wei Wei, Daniel Zelterman, Niamh Long, Isabel B. Oliva, Sarah B. Goldberg, Roy S. Herbst, Jungmin Choi, M. Ladanyi, Francisco Sanchez-Vega, Aaron Lisberg, Darragh Halpenny, Matthew D. Hellmann, Katherine Hastings, Guoping Cai, B.S. Henick, Mark M. Awad
Publikováno v:
Annals of Oncology
Background Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumor
Autor:
Mark G. Kris, Francisco Sanchez-Vega, Gregory J. Riely, Maria E. Arcila, Marc Ladanyi, Michael Offin, Megan Tenet, Alexander Drilon, Nikolaus Schultz, Bob T. Li, Andy Ni, Hira Rizvi, Helena A. Yu, Matthew D. Hellmann, Charles M. Rudin
Publikováno v:
Clinical Cancer Research. 25:1063-1069
Purpose: Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact of TMB on outcomes with targeted therapies has not been explored. Experimental Design: We identified all patients with metastatic EGFR exo
Autor:
Subba R. Digumarthy, Mustafa Sakhi, Hira Rizvi, Michelle S. Ginsberg, Andrew J. Plodkowski, Jia Luo, Jeffrey Girshman, Kevin B. Huang, Regina Barzilay, Gregory J. Riely, Kathryn C. Arbour, Matthew D. Hellmann, Anh Tuan Luu, Mark G. Kris, Justin F. Gainor, Adam Yala
Publikováno v:
Cancer Discov
Real-world evidence (RWE), conclusions derived from analysis of patients not treated in clinical trials, is increasingly recognized as an opportunity for discovery, to reduce disparities, and to contribute to regulatory approval. Maximal value of RWE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d3894f7ad0aa8b4e63aef9a7c4ebcc4
https://europepmc.org/articles/PMC7981277/
https://europepmc.org/articles/PMC7981277/